Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.
OBJECTIVE
To evaluate the initial, long-term, and durable response rates to terazosin, placebo, or other therapies in patients with chronic prostatitis/chronic pelvic pain syndrome.


METHODS
A total of 100 subjects, aged 20 to 50 years, who met the National Institutes of Health criteria for chronic prostatitis/chronic pelvic pain syndrome and had not previously been treated with alpha-blockers, were entered in a 14-week, double-blind comparison of terazosin or placebo therapy. Nonresponders and responders with subsequent relapse were treated with terazosin or other medications (open label). The criterion for response was a score of 0 to 2 on the National Institutes of Health Chronic Prostatitis Symptom Index quality-of-life item. The initial response was evaluated at week 14, and the long-term response was evaluated after a median of 38 weeks (range 34 to 42), regardless of any additional treatment. A durable response was defined as an initial response without additional treatment.


RESULTS
Of the 43 patients in the terazosin group, 24 (56%) had an initial response compared with 14 (33%) of 43 subjects in the placebo group (P = 0.03). Long-term responses were noted in 23 (56%) of 41 assessable subjects treated with terazosin initially compared with 12 (32%) of 38 assessable subjects treated with placebo (P = 0.03). Of the nonresponders and initial responders with relapse, 7 (41%) of 17 subjects responded to terazosin compared with 7 (21%) of 34 given other treatment (P = 0.12). Durable responses occurred in 18 (44%) of the 41 assessable patients treated initially with terazosin and in 6 (16%) of 38 treated initially with placebo (P = 0.01).


CONCLUSIONS
Patients treated with terazosin were more likely to have initial, long-term, and durable responses than those treated with placebo.
Cheah
Phaik Yeong
PY
University of Science Malaysia School of Pharmaceutical Sciences, Penang, Malaysia.
Liong
Men Long
ML
Yuen
Kah Hay
KH
Teh
Chu Leong
CL
Khor
Timothy
T
Yang
Jin Rong
JR
Yap
Hin Wai
HW
Krieger
John N
JN
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D002908:Chronic Disease; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017699:Pelvic Pain / Q000188:drug therapy*; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011472:Prostatitis / Q000188:drug therapy*; D011788:Quality of Life; D012107:Research Design; D013577:Syndrome; D013997:Time Factors
D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin